Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer

摘要: The past 15 years has seen a marked increase in available therapeutic options for patients with metastatic colorectal cancer resulting improvements median survival from 12 to 24 months. One of these new is panitumumab, which fully humanized monoclonal antibody that binds the epidermal growth factor receptor tumor cells and inhibits downstream cell signaling antitumor effects inhibition growth, induction apoptosis angiogenesis. Large randomized clinical trials have demonstrated significant response rates progression-free when panitumumab combined chemotherapy as monotherapy chemorefractory cancer. Clinical benefit limited nonmutated KRAS tumors. Rash common toxicity treatment but can potentially be ameliorated use prophylactic strategies. role overall evolving future will focus on improved patient selection through novel predictive biomarkers, optimal timing treatment.